Clinical trials: DCIS
Breast Cancer
Anastrozole or Tamoxifen in Treating Postmenopausal Women With Ductal Carcinoma in Situ Who Are Undergoing Lumpectomy and Radiation Therapy
RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Tamoxifen may fight breast cancer by blocking the use of estrogen. Anastrozole may fight breast cancer by decreasing estrogen production.
- Trial name
- NCT00053898
- Testing
- anastrozole, tamoxifen citrate, Radiation Therapy
- Where
- 740 sites in United States, Canada and 1 more
- Volunteers
- 3,104 people
- Sponsor
- NSABP Foundation Inc
Breast Neoplasms
Exemestane and Celecoxib in Postmenopausal Women at High Risk for Breast Cancer
The primary goal of this 5-year study is to determine whether exemestane alone or in combination with celecoxib decreases breast tissue density in healthy postmenopausal women at high risk for breast cancer.
- Trial name
- NCT00073073
- Testing
- Exemestane, Calcium carbonate, Vitamin D
- Where
- 2 sites in United States
- Volunteers
- 46 people
- Sponsor
- Georgetown University
Breast Cancer
Tamoxifen or Letrozole in Treating Women With Ductal Carcinoma in Situ
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using tamoxifen or letrozole may fight breast cancer by blocking the use of estrogen by the tumor cells or by lowering the amount of estrogen the…
- Trial name
- NCT00290745
- Testing
- letrozole, tamoxifen citrate, conventional surgery
- Where
- United States
- Volunteers
- 79 people
- Sponsor
- University of California, San Francisco
Ductal Carcinoma In Situ
Neoadjuvant Herceptin for Ductal Carcinoma In Situ of the Breast
Primary Objectives: To determine the effect of a single dose of Herceptin (trastuzumab) on the proliferation rate of Her-2/neu over-expressing ductal carcinoma in situ (DCIS) To evaluate the effect of a single dose of Herceptin…
- Trial name
- NCT00496808
- Testing
- Herceptin (Trastuzumab)
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- M.D. Anderson Cancer Center